RECOVERY & TISSUE REPAIR / MATRIX
Three Repair Mechanisms, Three Very Different Evidence Bases
How a matrix-synthesis peptide, an actin-signaling fragment, and an untested two-peptide blend differ in what has actually been shown.
The short version
This page lines up GHK-Cu, TB-500, and Wolverine on the dimensions that matter most for reading recovery-and-repair peptide research: mechanism, evidence base, regulatory status, and the single biggest caution for each. The short version: GHK-Cu has the most human evidence, entirely topical and cosmetic. TB-500 has one solid human safety trial — but for a different, full-length molecule, not the fragment sold under that name. Wolverine has no evidence of its own at all; its case rests entirely on the separate literatures of its two components, with no study of the combination. None of these three is an approved systemic medicine, and nothing on this page is a recommended dose or course of action for a person.
The comparison matrix
| Dimension | GHK-Cu | TB-500 | Wolverine (BPC-157 + TB-500) |
|---|---|---|---|
| Mechanism | Copper-binding tripeptide; drives dermal fibroblast collagen/elastin/GAG synthesis and matrix remodeling [4][6] | Synthetic fragment of thymosin beta-4; reasoned to regulate actin dynamics behind cell migration [10][12] | Combines BPC-157 (VEGFR2-driven angiogenic/cytoprotective signal [15]) with TB-500's actin signal; no combined mechanism study |
| Most-studied context | Topical skin/hair, cosmetic dermatology | Preclinical injury models (stroke, wound); one IV human safety trial of the parent protein [11] | Musculoskeletal/tendon research use; each component studied separately, never together |
| Evidence base | Small human trials (n=13-71) plus in vitro/animal work [1][3][4][5][7] | Almost entirely preclinical; a 2026 review flags scarce human safety data across this peptide class [8][9] | Zero combination-specific studies; two BPC-157 reviews find no clinical safety data and no mention of TB-500 [13][14] |
| Human trials | Small topical/hair studies [3][4] | One (IV thymosin beta-4, not the TB-500 fragment) [11] | None for the blend; none for TB-500; three small BPC-157 pilot studies only [14] |
| Regulatory status | Legal cosmetic ingredient (Copper Tripeptide-1); no approved drug indication | Not approved for human use; WADA-prohibited | Neither component approved; both WADA-prohibited |
| Key caution | Injectable/systemic use is unapproved and unstudied in humans | Human safety essentially unstudied for the fragment itself [8] | The combination has never been tested; safety of the pairing is genuinely unknown [13][14] |
Mechanism
The three members work through genuinely different biology, which is part of why they are grouped by theme rather than by mechanism. GHK-Cu operates extracellularly and at the gene-expression level: it is a documented driver of dermal fibroblast collagen, elastin, and glycosaminoglycan synthesis, and shifts expression of roughly 31.2% of human genes at a 50%-or-greater threshold toward wound-repair, antioxidant, and protein-quality-control programs [2][4][6]. TB-500 operates intracellularly: as a fragment of thymosin beta-4, it is reasoned to sequester monomeric actin and regulate the cytoskeletal dynamics that let cells migrate into an injury site [10][12]. Wolverine combines TB-500's proposed mechanism with a second, separate one from BPC-157 — upregulation of the VEGFR2 receptor and its downstream angiogenic Akt-eNOS signaling [15] — reasoned as complementary because the two pathways barely overlap. That non-overlap is a hypothesis, not a tested result: no study has measured the two mechanisms operating together.
Evidence base
This is where the three separate most sharply. GHK-Cu has the deepest human evidence of the three: multiple small, controlled topical and hair trials (n=13-71), decades of cosmetic-safety experience, and a substantial in vitro and gene-expression literature [1][3][4][5][7]. TB-500's efficacy evidence is almost entirely preclinical — rodent stroke and wound models — with a single completed human trial that tested full-length thymosin beta-4 delivered intravenously, not the fragment sold as TB-500 [9][11]. Wolverine has no evidence base of its own: its two components have been studied separately (BPC-157 in 36 studies, only one of them human, per a 2025 systematic review; TB-500 with no completed human efficacy trials at all), but no published study has tested the combination [13][14].
Regulatory and approval status
None of the three is an approved systemic medicine. GHK-Cu's topical form, Copper Tripeptide-1, is a legal, widely marketed cosmetic ingredient in the US, EU, and UK; injectable or other systemic use has no established regulatory pathway. TB-500 has no approved therapeutic indication anywhere and is prohibited by the World Anti-Doping Agency under peptide and growth-factor categories, with confirmed anti-doping detection methods. Wolverine inherits both restrictions: BPC-157 falls under WADA's non-approved-substances category and was flagged by the FDA in 2023 as ineligible for pharmacy compounding pending further evaluation, while TB-500 carries the same WADA-prohibited status described on its own page. Material sold under any of these three names is distributed as a research chemical, not a regulated drug product.
Key caution
Each member carries a defining caveat. For GHK-Cu, everything well documented is topical — injectable or otherwise systemic use is unapproved and has essentially no human safety data behind it. For TB-500, it is the identity gap: the one well-conducted human tolerability study used a different, full-length molecule, not the short fragment sold under this name. For Wolverine, it is more fundamental still — the combination itself has simply never been studied, so its safety is not merely unclear, it is unmeasured. Reading the three together, the pattern is consistent: more complexity, moving from single peptide to fragment to combination, has so far meant less direct evidence, not more.